Dalnicastobart Biosimilar - Research Grade

Human

CD40

>1mg/ml

IgG1 - kappa

CHO Cells

Anti-Mouse CD40 (FGK4.5) In Vivo Antibody - Low Endotoxin (ICH1073), Bulk Anti-Human CD40 (G28.5) Antibody (ICH1156), Dacetuzumab Biosimilar - Research Grade (ICH5030), Sotigalimab Biosimilar - Research Grade (ICH5031), Selicrelumab Biosimilar - Research Grade (ICH5032), Lucatumumab Biosimilar - Research Grade (ICH5129), Abiprubart Biosimilar - Research Grade (ICH5323), Bleselumab Biosimilar - Research Grade (ICH5407), Cifurtilimab Biosimilar - Research Grade (ICH5437), Giloralimab Biosimilar - Research Grade (ICH5571), Iscalimab Biosimilar - Research Grade (ICH5610), Mitazalimab Biosimilar - Research Grade (ICH5689), Ravagalimab Biosimilar - Research Grade (ICH5806), Teneliximab Biosimilar - Research Grade (ICH5915)

https://www.imgt.org/mAb-DB/

ICH3002

P25942

Blue ice

ICH5462 is a research-grade biosimilar of dalnicastobart, supplied as an unconjugated, non-therapeutic recombinant analog for research use only. It is built around the sequence and binding characteristics of the originator antibody, a human IgG1 (kappa light chain) directed against human CD40 (TNFRSF5, UniProt P25942). Dalnicastobart (also reported as LVGN-7409) is an investigational agonistic anti-CD40 antibody explored in oncology, where CD40 engagement is intended to activate antigen-presenting cells and support anti-tumor immunity. This product is not a formulated drug and is not intended for clinical or therapeutic use; it is a laboratory reagent for in-vitro and functional characterization work. Because CD40 is a human target, this molecule is primarily suited to studies of human CD40 biology rather than routine mouse in-vivo dosing models. It is manufactured to low-endotoxin research standards and is available in bulk milligram-to-gram quantities, making it appropriate for assay development, comparability studies, and mechanistic experiments requiring a defined, sequence-matched anti-CD40 IgG1 reference reagent. CD40 (TNFRSF5, UniProt P25942) is a type I transmembrane receptor of the tumor necrosis factor receptor superfamily, expressed on dendritic cells, B cells, macrophages, and other antigen-presenting cells, as well as on some non-immune and tumor cells. Its natural ligand is CD40L (CD154), expressed largely on activated CD4+ T cells. CD40-CD40L engagement is a central co-stimulatory axis: it licenses dendritic cells to prime CD8+ effector T-cell responses and drives B-cell activation, proliferation, class-switch recombination, and differentiation. Signaling proceeds through TRAF adaptor recruitment and downstream NF-kB and MAPK pathways. Because of this immunostimulatory role, agonistic CD40 targeting is an active area of cancer immunotherapy, while CD40 blockade is studied in autoimmune and transplant settings. CD40 is a human-restricted target here, so this reagent is most relevant to human CD40 pathway studies.

CD40, Bp50, CDW40, TNFRSF5, p50, CD40 (protein), CD40 molecule

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks